Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Vidal, Liat ^a   Ben dor, Itsik ^a   Paul, Mical ^b   Eliakim Raz, Noa ^a   Pokroy, Ellisheva ^a   Soares Weiser, Karla ^c   Leibovici, Leonard ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Central Office   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

AGE; ANTIBIOTIC THERAPY; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MORTALITY RATE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; NEOPLASM; ORAL DRUG ADMINISTRATION; TREATMENT FAILURE; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; NEOPLASMS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; HUMANS; INJECTIONS, INTRAVENOUS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84899468576     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003992.pub3     Document Type: Review

References (109)

1. Brack E, Bodmer N, Simon A, Leibundgut K, Kühne T, Niggli FK, et al.First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood & Cancer 2012;59(3):423-30.
2. Lüthi F, Leibundgut K, Niggli FK, Nadal D, Aebi C, Bodmer N, et al.Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood & Cancer 2012;59(1):90-5.
3. Cagol AR, Castro Junior CG, Martins MC, Machado AL, Ribeiro RC, Gregianin LJ, et al.Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. Jornal de Pediatria 2009;85(6):531-5.
4. Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, et al.Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology 2004;79(1):74-8. [MEDLINE: 14979482]
5. Flaherty JP, Waitley D, Edlin B, George D, Arnow P, O'Keefe P, et al.Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. The American Journal of Medicine 1989;87 Suppl:278-82.
6. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al.A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. The New England Journal of Medicine 1999;341(5):305-11.
7. Giamarellou H, Bassaris HP, Petrikkos G, Busch W, Voulgarelis M, Antoniadou A, et al.Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy 2000;44:3264-71.
8. Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. Journal of Pediatric Hematology/Oncology 2009;31(9):635-41.
9. Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, et al.Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213-9.
10. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with inpatient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Data on file.
11. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England Journal of Medicine 1999;341:312-8.
12. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
13. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, et al.Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126-34.
14. Mullen CA, Petropoulos D, Roberts WM, et al.Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. Journal of Pediatric Hematology/Oncology 1999;21:212-8.
15. Niho S, Ohe Y, Goto K, H Ohmatsu, T Matsumoto, K Kubota, et al.Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Japanese Journal of Clinical Oncology 2004;34(2):69-73. [MEDLINE: 15067098]
16. Paganini HR, Sarkis CM, De Martino MG, Zubizarreta PA, Casimir L, Fernandez C, et al.Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2000;88:2848-52.
17. Paganini H, Gomez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L, et al.Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2003;97(7):1775-80. [MEDLINE: 12655535]
18. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology 2000;34:87-91.
19. Rolston K, Rubenstein E, Elting L, Escalante C, Manzullo E, Bodey GP. Ambulatory management of febrile episodes in low-risk neutropenic patients. Interscience conference on antimicrobial agents and chemotherapy. 1995:LM81.
20. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al.Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
21. Anaissie EJ, Samonis G, Kalbakis K, Georgoulias V. Therapy for low-risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. Interscience conference on antimicrobial agents and chemotherapy. 1997:LM-51.
22. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, et al.Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer 2008;16(9):1017-23.
23. Shenep JL, Flynn PM, Baker DK, Hetherington SV, Hudson MM, Hughes WT, et al.Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease 2001;32:36-43.
24. Velasco E, Costa MA, Martins CA, Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology-Cancer Clinical Trials 1995;18(5):429-35.
25. Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. Pediatric Blood & Cancer 2007;49(6):786-92.
26. Ammann RA. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2004;100(7):1547; author reply 1547-8.
27. Aquino VM, Buchanan GR, Tkaczewski I, Mustafa MM. Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Medical and Pediatric Oncology 1997;28:191-5.
28. Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000;88:1710-4.
29. Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74(1):189-96.
30. Berrahal F, Baume D, Burtey S, Mazzerbo F, Zanlucca S, Demichelis C. A study of intravenous ticarcillin/clavulanic acid and oral ciprofloxacin in the treatment of febrile neutropenic patients. Journal de Pharmacie Clinique 1996;15(Special issue):74-7.
31. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, et al.Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005;103(12):2629-35. [MEDLINE: 15856427]
32. Chernobelski P, Lavrenkov K, Rimar D, Riesenberg K, Schlaeffer F, Ariad S, et al.Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients. Chemotherapy 2006;52(4):185-9.
33. Cometta A, Kern W. [Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group]. Presse Medicale 2004;33(5):327-9.
34. Cooper MR. Durand CR. Beaulac MT. Steinberg M. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia. Annals of Pharmacotherapy 2011;45(9):1094-102.
35. Cornelissen JJ, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clinical Infectious Diseases 1995;21:1300-2.
36. Dommett R, Geary J, Freeman S, Hartley J, Sharland M, Davidson A, et al.Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. European Journal of Cancer 2009;45(16):2843-9.
37. Escalante CP, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T, et al.Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Supportive Care in Cancer 2004;12(9):657-62.
38. Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clinical Journal of Oncology Nursing 2010;14(1):81-6.
39. Freifeld A, Pizzo P. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. The Pediatric Infectious Disease Journal 1997;16:140-5; discussion 145-6, 160-2.
40. Freifeld A, Sankaranarayanan J, Ullrich F, Sun J. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Supportive Care in Cancer 2008;16(2):181-91.
41. Freifeld AG, Sepkowitz KA. No place like home? Outpatient management of patients with febrile neutropenia and low risk. Journal of Clinical Oncology 2011;20(30):3952-4.
42. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Annals of Oncology 1991;2:485-7.
43. Guyotat D, Plonton C, Fiere D. A randomized trial of oral vancomycin in neutropenic patients. Progress in Clinical and Biological Research 1985;181:263-5.
44. Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology 2011;29(30):3984-9.
45. Horowitz HW, Holmgren D, Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leukemia and Lymphoma 1996;23(1-2):159-63.
46. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA 1994;272:1183-9.
47. Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KV. Bacterial infections in low-risk, febrile neutropenic patients. Cancer 2005;104(2):422-6.
48. Kern W. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clinical Infectious Diseases 2006;42(4):533-40.
49. Kibbler CC, Pomroy L, Sage RJ, Mannan P, Noone P, Prentice HG. The use of ciprofloxacin in the treatment of febrile neutropenic patients. Proceedings of the 33rd European Congress of Clinical Microbiology. 1987 11-14 May.
50. Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. Journal of Pediatric Hematology/Oncology 2000;22:405-11.
51. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al.Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of Clinical Oncology 2006;24(25):4129-34.
52. Lau RC, Doyle JJ, Freedman MH, King SM, Richardson SE. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Journal of Pediatric Hematology/Oncology 1994;11:417-21.
53. Leverger G. [Outpatient antibiotherapy in children with neutropenia and fever. A review of the literature.]. Presse Medicale 2004;33(5):330-7.
54. Lüthi F, Leibundgut K, Niggli FK, Nadal D, Aebi C, Bodmer N, et al.Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood & Cancer 2012;59(1):90-5.
55. Malik IA, Khan WA, Aziz Z, Karim M. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clinical Infectious Diseases 1994;19:522-7.
56. Malik IA, Aziz Z, Khan WA. A randomized trial to evaluate the role of ofloxacin in the out-patient management of neutropenic febrile patients. Annals of Oncology 1992;3 Suppl:197.
57. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. The American Journal of Medicine 1995;98:224-31.
58. Malik IA. Out-patient management of febrile neutropenia in indigent paediatric patients. Annals of the Academy of Medicine, Singapore 1997;26:742-6.
59. Marra CA, Frighetto L, Quaia CB, et al.A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy 2000;20:931-40.
60. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, et al.Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrobial Agents and Chemotherapy 1991;35(5):873-8.
61. Minotti V, Gentile G, Bucaneve G, Iori AP, Micozzi A, Cavicchi F, et al.Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Supportive Care in Cancer 1999;7:134-9.
62. Montalar Salcedo J, Oltra Ferrando A, Segura Huerta A, Santaballa Bertran A, Yuste Izquierdo A, Aparicio Urtasun J. Ofloxacin as monotherapy in the treatment of neutropenic fever. Oncologia 1999;22(8):42-7.
63. Mullen CA. Which children with fever and neutropenia can be safely treated as outpatients?. British Journal of Haematology 2001;112:832-7.
64. Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. The Journal of Pediatrics 1996;128(6):847-9.
65. Nepokul'chitskaia NV, Timakov AM, Kondratchik KL, Makhortykh T, Tarasova IS, Erina TA. [Cephalosporins in the treatment of children with oncohematologic diseases]. Antibiotiki i Khimioterapiia (Moskva) 1998;43:30-2.
66. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, Latella A, Firpo V, Casimir L, et al.Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 2001;91:1563-7.
67. Paganini H, Rodriguez-Brieshcke TR, Zubizarreta P, Latella A, Firpo V, Fernandez C. Validation of lower risk mortality profile in pediatric febrile neutropenia during cancer chemotherapy. Medicina 2001;61(1):63-6.
68. Papadimitris C, Dimopoulos MA, Kostis E, Papadimitriou C, Anagnostopoulos A, Alexopoulos G, et al.Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Oncology 1999;57:127-30.
69. Petrilli A, Altruda Carlesse F, Alberto Pires Pereira C. Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. Pediatric Blood & Cancer 2007;49(5):682-6.
70. Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatric Blood & Cancer 2007;48(3):273-7.
71. Rapoport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, et al.Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge versus standard in-patient care. Chemotherapy 1999;45(6):466-76.
72. Rolston KV, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault RL, et al.Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 2006;106(11):2489-94.
73. Rolston KVI, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Supportive Care in Cancer 2010;18(1):89-94.
74. Santolaya ME, Villarroel M, Avendano LF, Cofre J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clinical Infectious Diseases 1997;25(1):92-7.
75. Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Cumsille MA, et al.Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology 2004;22(18):3784-9.
76. Sato T, Kobayashi R, Yasuda K, Kaneda M, Iguchi A, Kobayashi K. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatric Blood & Cancer 2008;51(6):774-7.
77. Slavin MA, Grigg AP, Schwarer AP, Szer J, Spencer A, Sainani A, et al.A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40(2):157-63.
78. Talcott JA, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, et al.Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology 2011;29(30):3977-83.
79. Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. International Journal of Antimicrobial Agents 2005;26 Suppl 2:S123-7; discussion S133-40.
80. Timmers GJ, Simoons-Smit AM, Leidekker ME, Janssen JJ, Vandenbroucke-Grauls CM, Huijgens PC. Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. Clinical Microbiology and Infection 2007;13(5):497-503.
81. Uzun O, Anaissie EJ. Outpatient therapy for febrile neutropenia: who, when, and how?. Journal of Antimicrobial Chemotherapy 1999;43(3):317-20.
82. Vallejo C, Caballero MD, Garcia-Sanz R, Hernandez JM, Vazquez L, Canizo MC, et al.Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematology & Cell Therapy 1997;39(5):223-7.
83. Wacker P, Halperin DS, Wyss M, Humbert J. Early hospital discharge of children with fever and neutropenia: a prospective study. Journal of Pediatric Hematology/Oncology 1997;19(3):208-11.
84. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966;64(2):328-40.
85. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Diseases 1990;161(3):397-401.
86. EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. European Journal of Cancer 1990;26(5):569-74.
87. Feld R. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?. Supportive Care in Cancer 1998;6(5):444-8.
88. Feld R. Multinational cooperation in trials and guidelines dealing with febrile neutropenia. International Journal of Antimicrobial Agents 2000;16(2):185-7.
89. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV, et al.Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinical Infectious Diseases 2002;35(12):1463-8.
90. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). British Journal of Haematology 1997;99(3):580-8.
91. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Oxford: Update Software, updated quarterly.
92. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002;34(6):730-51.
93. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36-9.
94. Kern WV. Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Current Opinion in Infectious Diseases 2001;14(4):415-22.
95. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology 2000;18(5):1012-9.
96. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al.The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology 2000;18(16):3038-51.
97. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996;77(4):791-8.
98. Paesmans M. Risk factors assessment in febrile neutropenia. International Journal of Antimicrobial Agents 2000;16(2):107-11.
99. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patients with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61(3):153-65.
100. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in childen with fever and neutropenia. Journal of Clinical Oncology 1996;14(3):919-24.
101. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clinical infectious diseases 1999;29(3):515-21.
102. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. The New England Journal of Medicine 1971;284(19):1061-5.
103. Schimpff S. Empiric antibiotic therapy for granulocytopenic cancer patients. The American Journal of Medicine 1986;80(5C):13-20.
104. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. JAMA 1995;273(5):408-12.
105. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Archives of Internal Medicine 1988;148(12):2561-8.
106. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology 1992;10(2):316-22.
107. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. Journal of Clinical Oncology 1994;12(1):107-14.
108. Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). European Journal of Cancer 2002;38 Suppl 4:S82-7.
109. Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. Journal of Antimicrobial Chemotherapy 2004;54(1):29-37.